secwatch.observer — SEC 8-K summary
======================================

Issuer:     LIFECORE BIOMEDICAL, INC. DE (LFCR)
CIK:        0001005286
Form:       8-K
Filed at:   2026-05-06T23:59:59+00:00
Accession:  0001005286-26-000018
Event type: earnings
Sentiment:  negative
Materiality: 0.72
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lifecore Biomedical Q1 revenue $23.2M (-34% YoY), net loss $15.0M, reaffirms FY2026 guidance
--------------------------------------------------------------------------------

- Revenue $23.2M, down 34% from $35.2M; gross margin 19% vs 28% prior year.
- Net loss $15.0M ($0.43 loss per diluted share) vs $14.8M loss year ago.
- Adjusted EBITDA $1.0M, down $4.7M from $5.7M; operating expenses cut 52%.
- Signed three new commercial site transfer programs in Q1; reaffirms full-year 2026 guidance.
- Liquidity $38.1M (cash $20.8M, revolver $17.3M); free cash flow $3.6M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1005286/000100528626000018/0001005286-26-000018-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1005286/000100528626000018/lndc-20260506.htm
  HTML page:      https://secwatch.observer/filing/0001005286-26-000018

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer